Sanofi Pasteur Parterners with International Vaccine Institute against Dengue

Sanofi Pasteurhas entered into a partnership with the International Vaccine Institute to remove dengue threat.

Sanofi Pasteur, the vaccines division of sanofi-aventis Group announced that it has entered into a partnership with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI).

Currently, there is no specific treatment available for dengue fever, which is a threat to nearly half of the world's population and a public health priority in many countries of Latin America and Asia where epidemics occur. Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global health agenda.

Of the estimated 220 million people infected annually, two million - mostly children - develop dengue hemorrhagic fever (DHF), a severe form of the disease. DHF is a leading cause of hospital